Clinical Trials Logo

Clinical Trial Summary

Chronic renal failure (CKD) is defined as a chronic, progressive degeneration in the kidney's fluid-electrolyte balance and metabolic-endocrine functions as a result of the glomerular filtration rate (GFR) falling below 60 ml/min/1.73 m², regardless of the etiology of the kidney disease. CRF is divided into five stages according to the glomerular filtration rate. Stage V is end-stage renal disease (ESRD), a life-threatening condition in which GFR falls below 15 ml/min/1.73 m2. ESRD patients have to receive dialysis [hemodialysis (HD), peritoneal dialysis (PD)] or kidney transplantation (Tx) under the name of renal replacement therapies (RRT) in order to survive and to support the metabolic hemostatic function of the kidney. Although the majority of ESRD patients survive on dialysis, their quality of life and functional capacity are reduced due to uremic cardiomyopathy, cardiovascular diseases, anemia, diabetes mellitus, bone diseases, deconditioning, fatigue, weakness, inactivity and accompanying psychological problems. In addition, due to the burden of chronic disease and the necessity of being dependent on machinery, patients are also faced with the risk of losing their job, addiction in daily life activities, depression, anxiety, changes in body image, financial problems, sexual problems, social isolation, mortality and hospitalization. Intradialytic exercise (IDE) is defined as exercise training performed during the hemodialysis session to increase the patient's strength and endurance and thus target various physiological and psychosocial parameters. Patients' choice of exercise depends on individual factors such as medical history, physical capacity, and transportation options, which are associated with cost and overall preferences. In this context, exercise programs during dialysis and at home are more preferred by patients due to the lack of transfer problems and loss of time. The exercise rehabilitation program to be chosen should also have features such as being practical, low cost and sustainable for patients receiving dialysis. Intradialytic exercise is a common recommendation to encourage patients to be physically active. Previous studies have shown that intradialytic exercise can reduce the severity of fatigue, improve sleep quality, increase exercise tolerance, improve life He claimed that it was effective in improving the quality of life and even improving the psychological state. Patients typically undergo two or three hemodialysis sessions per week, with each session lasting approximately 4 hours. As many patients maintain bed rest during hemodialysis sessions, intradialytic exercise can be a potentially useful approach to improve their health without spending extra time in the interdialytic period. Although exercise variety is limited during hemodialysis sessions, intradialytic exercise maximizes the use of HD time. In addition, intradialytic exercise has been reported to increase patient compliance. However, conflicting data on the effects of intradialytic exercise have been reported. Intradialytic exercise (IDE) is not yet a routine practice for hemodialysis patients, an important reason is the lack of guidelines to support it. Intradialytic exercise is rarely given as standard of care, although numerous small studies have demonstrated the multiple benefits and safe practice of intradialytic exercise training for patients with end-stage renal disease. The aim of our study is to investigate the effect of intradialytic exercises on functional capacity and quality of life, although it is known that it can be done without spending extra time and is more preferred by patients, which is not routinely applied and needs more studies on its effects.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05246956
Study type Interventional
Source Istanbul Medipol University Hospital
Contact Ozal Keles, Master
Phone +90 5539602252
Email okeles@biruni.edu.tr
Status Recruiting
Phase N/A
Start date June 1, 2021
Completion date December 1, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Completed NCT01545531 - Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance N/A
Recruiting NCT05700903 - Contributions to Hypertension With Androgen Deprivation Therapy Phase 4
Completed NCT03717883 - ADPKD Alterations in Hepatic Transporter Function
Withdrawn NCT04556721 - A Pharmacokinetic Study of Sugammadex in Dialysis Patients Phase 1
Recruiting NCT04078750 - PLATO - Medication Adherence in Transplant Recipients N/A
Not yet recruiting NCT04531124 - Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives
Completed NCT03107195 - Biokinetics Study of Tc-99m DMSA in Pediatric Molecular Imaging
Completed NCT03463148 - Validation of a Sensor for Non-Invasive Measurements
Recruiting NCT03578523 - Renal MR Feasibility in Renal Disease
Withdrawn NCT01468259 - A Multi-Center, Open-Label Study Phase 1
Completed NCT01256983 - Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation Phase 0
Completed NCT06070337 - H-Guard Pilot Safety Evaluation in Haemodialysis Patients N/A
Completed NCT05593211 - Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures N/A
Completed NCT03242343 - VasQ External Support for Arteriovenous Fistula N/A
Completed NCT03438123 - Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera N/A
Completed NCT01334333 - Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients Phase 4
Recruiting NCT05443321 - Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes N/A
Completed NCT04407182 - Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 Phase 2
Not yet recruiting NCT04834089 - Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases Phase 1/Phase 2